Janssen Pharmaceuticals (Johnson & Johnson) has entered the game, folks. The hearing loss drug discovery game, that is.
a9α10 receptor modulators emerge as a novel therapeutic strategy for hearing loss.
Introducing α9α10:
Researchers recently identified a target that could be used to treat hearing loss and a handful of related auditory disorders -- including tinnitus -- and soon we may have another promising hearing restoration 'horse in the race'.
What's happening -- May 22, 2021 update:
This week, David S. Bredt -- molecular neuroscientist and Global Head Discovery Neuroscience at Johnson & Johnson -- will be presenting the recent findings at The Inner Ear Disorders Therapeutics Summit, an upcoming digital conference taking place a few days from now (May 25 - 27).
His presentation is titled:
Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss
Link:
Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss
Article:
Promising targets for deafness drug discovery
...the race to find a cure seems to be getting more interesting by the day -- with new and unexpected participants joining the action, sometimes out of nowhere.
a9α10 receptor modulators emerge as a novel therapeutic strategy for hearing loss.
Introducing α9α10:
Researchers recently identified a target that could be used to treat hearing loss and a handful of related auditory disorders -- including tinnitus -- and soon we may have another promising hearing restoration 'horse in the race'.
What's happening -- May 22, 2021 update:
This week, David S. Bredt -- molecular neuroscientist and Global Head Discovery Neuroscience at Johnson & Johnson -- will be presenting the recent findings at The Inner Ear Disorders Therapeutics Summit, an upcoming digital conference taking place a few days from now (May 25 - 27).
His presentation is titled:
Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss
Link:
Targeting the α9α10 Nicotinic Acetylcholine Receptor for Hearing Loss
Article:
Promising targets for deafness drug discovery
...the race to find a cure seems to be getting more interesting by the day -- with new and unexpected participants joining the action, sometimes out of nowhere.